Sökning: onr:"swepub:oai:DiVA.org:liu-108937" >
Impact of Once- Ver...
Impact of Once- Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes: An Analysis of the CATIE Data
-
- Takeuchi, Hiroyoshi (författare)
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada and Keio University School of Medicine, Tokyo, Japan
-
- Fervaha, Gagan (författare)
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
-
- Uchida, Hiroyuki (författare)
- Keio University School of Medicine, Tokyo, Japan and Centre for Addiction and Mental Health, Toronto, Ontario, Canada
-
visa fler...
-
- Suzuki, Takefumi (författare)
- Keio University School of Medicine, Tokyo, Japan and Inokashira Hospital, Tokyo, Japan
-
- Bies, Robert R. (författare)
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada and Indiana Clinical and Translational Sciences Institute, Indianapolis, USA
-
- Grönte, David (författare)
- Östergötlands Läns Landsting,Psykiatriska kliniken
-
- Remington, Gary (författare)
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
-
visa färre...
-
(creator_code:org_t)
- Physicians Postgraduate Press, 2014
- 2014
- Engelska.
-
Ingår i: Journal of Clinical Psychiatry. - : Physicians Postgraduate Press. - 0160-6689 .- 1555-2101. ; 75:5, s. 506-511
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.4...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: The objective of this study was to evaluate the impact of once- versus twice-daily dosing of perphenazine, which has a plasma half-life of 8–12 hours, on clinical outcomes in patients with schizophrenia.Method: Data from phase 1 of the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) conducted between January 2001 and December 2004 were used in this post hoc analysis. Patients with schizophrenia (DSM-IV) randomly allocated to treatment with perphenazine were also randomly assigned to once-daily (N = 133) or twice-daily (N = 124) dosing and followed over 18 months. Discontinuation rate and time to discontinuation were used as primary outcomes to compare the 2 groups. The following clinical outcomes were analyzed as secondary measures: efficacy—Positive and Negative Syndrome Scale, Clinical Global Impressions-Severity scale, Calgary Depression Scale for Schizophrenia, and Drug Attitude Inventory and safety/tolerability—Abnormal Involuntary Movement Scale, Barnes Akathisia Rating Scale, Simpson-Angus Scale, and body weight. Data on treatment-emergent adverse events, concomitant psychotropic medications, and medication adherence (pill count and clinician rating scale) were also analyzed for each group.Results: No significant differences were found in any outcome measures between the once-daily and twice-daily dosing groups, which remained the same when using the mean dose of perphenazine as a covariate.Conclusions: Perphenazine is routinely administered in a divided dosage regimen because of its relatively short plasma half-life. However, the present findings challenge such a strategy, suggesting that once-daily represents a viable treatment option. Results are discussed in the context of more recent evidence that challenges the need for high and continuous dopamine D2 receptor blockade to sustain antipsychotic response..
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas